Metropolitan Life Insurance Co. NY held its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 11,660 shares of the biotechnology company’s stock at the end of the first quarter. Metropolitan Life Insurance Co. NY owned approximately 0.06% of Enanta Pharmaceuticals worth $359,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP boosted its position in shares of Enanta Pharmaceuticals by 129.7% in the first quarter. Dimensional Fund Advisors LP now owns 413,089 shares of the biotechnology company’s stock valued at $12,723,000 after buying an additional 233,265 shares in the last quarter. State Street Corp boosted its position in shares of Enanta Pharmaceuticals by 31.8% in the first quarter. State Street Corp now owns 748,824 shares of the biotechnology company’s stock valued at $23,063,000 after buying an additional 180,586 shares in the last quarter. Candriam Luxembourg S.C.A. boosted its position in shares of Enanta Pharmaceuticals by 50.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 356,000 shares of the biotechnology company’s stock valued at $10,965,000 after buying an additional 120,000 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Enanta Pharmaceuticals by 7.2% in the first quarter. Vanguard Group Inc. now owns 792,165 shares of the biotechnology company’s stock valued at $24,399,000 after buying an additional 53,007 shares in the last quarter. Finally, Virginia Retirement Systems ET AL boosted its position in shares of Enanta Pharmaceuticals by 127.1% in the first quarter. Virginia Retirement Systems ET AL now owns 64,500 shares of the biotechnology company’s stock valued at $1,987,000 after buying an additional 36,100 shares in the last quarter. 65.85% of the stock is owned by institutional investors.

Enanta Pharmaceuticals, Inc. (ENTA) traded down 3.92% during trading on Friday, hitting $37.96. 166,199 shares of the company traded hands. Enanta Pharmaceuticals, Inc. has a 12-month low of $21.52 and a 12-month high of $41.20. The stock has a 50-day moving average price of $37.76 and a 200-day moving average price of $32.76. The firm’s market capitalization is $724.66 million.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative return on equity of 7.74% and a negative net margin of 51.85%. The business had revenue of $7.51 million during the quarter, compared to the consensus estimate of $8.08 million. During the same quarter last year, the company earned ($0.06) EPS. The firm’s revenue was down 46.3% compared to the same quarter last year. Equities analysts expect that Enanta Pharmaceuticals, Inc. will post $0.90 EPS for the current fiscal year.

WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/20/metropolitan-life-insurance-co-ny-maintains-stake-in-enanta-pharmaceuticals-inc-enta.html.

ENTA has been the subject of several analyst reports. Zacks Investment Research cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 12th. ValuEngine raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. BidaskClub cut shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. JMP Securities raised shares of Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 target price for the company in a research note on Tuesday, July 11th. Finally, Robert W. Baird raised their target price on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, August 8th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Enanta Pharmaceuticals currently has an average rating of “Buy” and an average price target of $36.00.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Stock Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.